

Brilinta® (ticagrelor) - First-time generic

- On May 1, 2025, <u>Teva launched</u> an <u>AB-rated</u> generic version of AstraZeneca's <u>Brilinta (ticagrelor)</u> tablets.
 - Teva was granted 180-day exclusivity for the 60 mg tablet.
 - In addition, Dr. Reddy's, Hisun, Alkem/Ascend, MSN/Novadoz, <u>AvKare</u> and <u>Apotex</u> <u>launched</u> AB-rated generic versions of Brilinta's 90 mg tablet on May 1, 2025.
- Brilinta is approved for the following indications:
 - To reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome or a history of MI
 - To reduce the risk of a first MI or stroke in patients with coronary artery disease at high risk for such events
 - To reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack.
- Brilinta carries a boxed warning for bleeding risk.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.